Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.

We have developed a tumor vaccine in which patient-derived myeloma cells are chemically fused with autologous dendritic cells (DCs) such that a broad spectrum of myeloma-associated antigens are presented in the context of DC-mediated costimulation. We have completed a phase 1 study in which patients with multiple myeloma underwent serial vaccination with the DC/multiple myeloma fusions in conjunction with granulocyte-macrophage colony-stimulating factor. DCs were generated from adherent mononuclear cells cultured with granulocyte-macrophage colony-stimulating factor, interleukin-4, and tumor necrosis factor-α and fused with myeloma cells obtained from marrow aspirates. Vaccine generation was successful in 17 of 18 patients. Successive cohorts were treated with 1 × 10(6), 2 × 10(6), and 4 × 10(6) fusion cells, respectively, with 10 patients treated at the highest dose level. Vaccination was well tolerated, without evidence of dose-limiting toxicity. Vaccination resulted in the expansion of circulating CD4 and CD8 lymphocytes reactive with autologous myeloma cells in 11 of 15 evaluable patients. Humoral responses were documented by SEREX (Serologic Analysis of Recombinant cDNA Expression Libraries) analysis. A majority of patients with advanced disease demonstrated disease stabilization, with 3 patients showing ongoing stable disease at 12, 25, and 41 months, respectively. Vaccination with DC/multiple myeloma fusions was feasible and well tolerated and resulted in antitumor immune responses and disease stabilization in a majority of patients.

[1]  G. Giaccone,et al.  Targeting the dynamic HSP90 complex in cancer , 2010, Nature Reviews Cancer.

[2]  Chung Park,et al.  Variations in Gnai2 and Rgs1 Expression Affect Chemokine Receptor Signaling and the Organization of Secondary Lymphoid Organs , 2010, Genes and Immunity.

[3]  S. Mandrekar,et al.  Idiotype‐pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival , 2009, American journal of hematology.

[4]  Michael L. Wang,et al.  Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. , 2009, Blood.

[5]  N. Munshi,et al.  Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. , 2009, Blood.

[6]  P. Schellhammer,et al.  Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer , 2009, Cancer.

[7]  P. Kantoff,et al.  Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma , 2007, Journal of immunotherapy.

[8]  Jin Xie,et al.  Targeting Heat Shock Proteins for Immunotherapy in Multiple Myeloma: Generation of Myeloma-Specific CTLs Using Dendritic Cells Pulsed with Tumor-Derived gp96 , 2005, Clinical Cancer Research.

[9]  F. Zhan,et al.  NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. , 2005, Blood.

[10]  K. Samuel,et al.  Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia , 2005, British journal of haematology.

[11]  F. Ronchese,et al.  Dendritic Cells Loaded with Stressed Tumor Cells Elicit Long-Lasting Protective Tumor Immunity in Mice Depleted of CD4+CD25+ Regulatory T Cells1 , 2005, The Journal of Immunology.

[12]  D. Gabrilovich.  Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.

[13]  M. Atkins,et al.  Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses , 2004, Clinical Cancer Research.

[14]  P. Richardson,et al.  Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma , 2004, British journal of haematology.

[15]  Catherine J. Wu,et al.  Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. , 2004, Blood.

[16]  J. Prieto,et al.  CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination 1 , 2003, The Journal of Immunology.

[17]  H. Johnsen,et al.  Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. , 2003, Blood.

[18]  Steven A. Rosenberg,et al.  Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules1 , 2003, The Journal of Immunology.

[19]  D. Purdie,et al.  Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine , 2003, Cancer Immunology, Immunotherapy.

[20]  G. Mufti,et al.  Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell–leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination , 2002, Cancer Immunology, Immunotherapy.

[21]  B. Barlogie,et al.  Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. , 2002, Blood.

[22]  T. Braun,et al.  A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  D. Czerwinski,et al.  Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. , 2002, Blood.

[24]  Zihai Li,et al.  Cell Surface Targeting of Heat Shock Protein gp96 Induces Dendritic Cell Maturation and Antitumor Immunity1 , 2001, The Journal of Immunology.

[25]  T. Braun,et al.  Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. , 2001, Cancer research.

[26]  R. Steinman,et al.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.

[27]  B. Barlogie,et al.  Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. , 2001, Blood.

[28]  T. Ohno,et al.  Antitumor Effect of Immunizations With Fusions of Dendritic and Glioma Cells in a Mouse Brain Tumor Model , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[29]  S. Cannistra,et al.  Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity1 , 2000, The Journal of Immunology.

[30]  J. Cyster,et al.  RGS Molecule Expression in Murine B Lymphocytes and Ability to Down-Regulate Chemotaxis to Lymphoid Chemokines1 2 , 2000, The Journal of Immunology.

[31]  D. Kufe,et al.  Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. Avigan.  Dendritic cells: development, function and potential use for cancer immunotherapy. , 1999, Blood reviews.

[33]  D. Kufe,et al.  Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  L. Falo,et al.  Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. , 1998, Journal of immunology.

[35]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[36]  M. Albert,et al.  Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.

[37]  D. Kufe,et al.  Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells , 1997, Nature Medicine.

[38]  E. Gilboa,et al.  Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo , 1996, The Journal of experimental medicine.

[39]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[40]  B. Barlogie,et al.  Graft-versus-myeloma effect: proof of principle. , 1996, Blood.

[41]  M. Colombo,et al.  Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo , 1996, The Journal of experimental medicine.

[42]  L. Zitvogel,et al.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.

[43]  M. Moore,et al.  Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. , 1995, Journal of immunology.

[44]  Y. Hinoda,et al.  Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. , 1994, Journal of immunology.

[45]  R. Steinman,et al.  Proliferating dendritic cell progenitors in human blood , 1994, The Journal of experimental medicine.

[46]  M. Boccadoro,et al.  Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy , 2004, Leukemia.

[47]  A. Lefvert,et al.  Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. , 1995, Blood.

[48]  A. Gallamini,et al.  Allogeneic bone marrow transplantation in multiple myeloma. , 1987, Acta haematologica.

[49]  J. Schlom,et al.  Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. , 1984, Hybridoma.